Upstream Bio, Inc. - Common Stock (UPB)
2.7900
+0.0400 (1.45%)
NASDAQ · Last Trade: Oct 27th, 6:50 PM EDT
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
– Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected in the second half of 2025 –
By Upstream Bio · Via GlobeNewswire · March 12, 2025